WS #15818
Analyst sentiment is shifting lower for several stocks, with JPMorgan lowering price targets for TransMedics, BCE, Vulcan Materials, Southern, and T. Rowe Price. These downgrades reflect concerns about valuation and near-term growth prospects. In contrast, Abbott Laboratories reported positive Phase 3 data for its SKYRIZI treatment for Crohn's disease, boosting investor confidence in its healthcare pipeline. This divergence highlights the selective nature of current market opportunities, with healthcare showing resilience while financials and industrials face headwinds.
Earnings & Analyst Downgrades
Analyst sentiment is shifting lower for several stocks, with JPMorgan lowering price targets for TransMedics, BCE, Vulcan Materials, Southern, and T. Rowe Price. These downgrades reflect concerns about valuation and near-term growth prospects. In contrast, Abbott Laboratories reported positive Phase 3 data for its SKYRIZI treatment for Crohn's disease, boosting investor confidence in its healthcare pipeline. This divergence highlights the selective nature of current market opportunities, with healthcare showing resilience while financials and industrials face headwinds.